| Autor: |
A. A. Al-Angary, Sayed H. Khidr, Mohsen A. Bayomi, M. A. Al-Meshal |
| Rok vydání: |
1998 |
| Předmět: |
|
| Zdroj: |
International Journal of Pharmaceutics. 168:163-168 |
| ISSN: |
0378-5173 |
| DOI: |
10.1016/s0378-5173(98)00066-0 |
| Popis: |
Liposomal formulation containing cyclosporine A (CSA) were prepared. The most stable liposomes with the composition of CSA, dipalmitoylphosphatidyl choline (DPPC) and cholesterol (Chol.) in molar ratio 1:0.2:1, respectively were administered orally to New Zealand rabbits. The pharmacokinetic of the administered CSA was compared with that of the commercially available oily oral formulation of CSA (Sandimmune) at dose of 15 mg/kg. Cyclosporine concentration in blood was monitored using a radioimmunoassay method (RIA). A change in the pharmacokinetic parameters of CSA due to liposomal encapsulation was observed. A peak concentration was reached in 50 min in case of liposomes compared with 225 min in case of Sandimmune. The rate of absorption ( C max /AUC 0–∞ ) was significantly faster following the liposome administration. A significant difference in the area under the concentration curve (AUC 0–∞ ) was found and this was attributed to the difference in the terminal half-lives ( t 1/2 β ) which were 8.88±1.94 and 19.3±8.48 h for liposomes and Sandimmune preparations, respectively. The mean residence time (MRT) and the mean absorption time (MAT) were dramatically decreased following the administration of liposomal formulation. Generally, there was less inter-individual variation in the values of rate of absorption, t 1/2 β and MRT when CSA liposomes were orally administered compared to the administration of Sandimmune. Thus, an oral liposomal formulation for CSA can be developed to offer the advantages of low variability and fast onset of action. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect